APLUSA’s Post

Patients are at the centre of everything we do at ALLG. Our ALLG members are dedicated to medical research that drives better treatments and better lives for patients with all types of blood cancer. One such patient is Ivan Bubalo from NSW. In the latest edition of ALLG News, Ivan shares the story of his myeloma diagnosis and treatment as part of an ALLG myeloma clinical trial. Clinical trials are the only way to advance new treatments that improve patient outcomes and quality of life while aiming for a cure. ALLG is the only not-for-profit, collaborative blood cancer clinical trial research group in Australia and New Zealand. Read Ivan’s inspiring story and all about ALLG’s research in ALLG News Edition 7 at: https://lnkd.in/gXi_Ywqd #ALLG #ALLGtrials #bettertreatmentsbetterlives #clinicaltrials   #bloodcancer #bloodcancerawareness #bloodcancercure #bloodcancers #haematology #haematologyresearch #leukaemiaandlymphoma #myeloma #myelomaawareness

🌟 Unveiling the power of synergy on this Friday read from IFO - Istituto Nazionale Tumori Regina Elena - Istituto Dermatologico San Gallicano 👉https://bit.ly/3wJkVAB Read how nCounter and GeoMx together help decode unexplored cellular and molecular mysteries driven by the dynamic actin regulator hMENA. 🧫 Learn about its influence on lung cancer patients' prognosis, Tertiary Lymphoid Structures, and the potential impact on immunotherapy response. #spatialbiology #immunotherapy #LungCancer

If you missed Dr. Rahul Banerjee's presentation on MedNews Week, don't worry! Catch up on the replay linked below, where he discusses CAR T cell therapy for multiple myeloma. Dr. Banerjee is a prominent oncologist, assistant professor, and researcher at the Fred Hutchinson Cancer Center. Link: https://lnkd.in/g6mhiWM6 Thanks to our amazing team at MedNews Week for making this a possibility: Yan Leyfman, MD Maduri Balasubramanian, Shreevikaa Kannan, Soumiya Nadar ,Rabab Hunaid Abbas, Emad Bin Zahid, Ahmed Hashim Azeez, Vallabhaneni Sree Harshitha, Muskan Joshi,  Helena Sanchez Coloma, Alexandra Van de Kieft, Harshal C., Gayathri Pramil Menon, Jade Gambill, Fabiha Amin, Adhith Theyver #ImmuneWarriors #CancerAndImmunity #FightCancerWithImmunity #ImmuneResponse #CancerImmunityConnection #BoostImmunityFightCancer #Immunotherapy #CancerImmunology #ImmuneSystemStrength #CancerDefense #ImmunologyResearch #CancerImmuneTherapy #StrongImmuneSystem #CancerImmunotherapy #ImmuneSupportAgainstCancer #ImmunocompromisedCancer #CancerImmuneResponse #ImmuneResilience #CancerAndImmuneHealth #ImmunologicalCancerResearch #HealthEquity #HealthJustice #InclusiveResearch #EmpoweredPatient #cancer #cancersucks #cancermemes #cancersurvivor #cancerawareness #cancerousmemes #cancerous #cancerresearch #cancerfree #cancerfighter #cancerwarrior #cancermeme #cancersupport #cancerprevention #cancersurvivors

💡 NEW FINDINGS: A recent CCR advance featured in Cancer Cell (Cell Press) identified several tumor-specific features and microenvironmental patterns in follicular lymphoma patients who experience early relapse. Understanding these factors may inform the selection of novel therapeutic approaches for these patients. National Cancer Institute (NCI), National Institutes of Health (NIH): Intramural Research Program (IRP) Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide. Most patients have widespread disease at diagnosis. Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present. ➡ Read the full article here: https://lnkd.in/e_Bcidjw #CancerResearch #Lymphoma #Health #Innovation #Medicine

Exciting data presented by Dr. Andrew Nixon from Duke Cancer Institute and Dr. Fábio C. P. Navarro from Personalis at #ASCO24! In a study with 33 patients with metastatic esophagogastric cancer (mEGC) treated with pembrolizumab combined with oxaliplatin and capecitabine, NeXT Personal® demonstrated 100% baseline detection. Molecular progression based on ctDNA increases, consistently preceded imaging progression, with a median lead time of 55 days (~2 months). Patients exhibiting an early decrease or clearance in ctDNA levels showed significant improvement in overall survival (OS) (p-value=0.002 and 0.005, respectively) and progression-free survival (PFS) (p-value=0.005 and 0.012, respectively). These results are suggestive that an ultra-sensitive liquid biopsy platform could improve treatment decision-making for patients receiving ICB. Want to learn more about NeXT Personal? Visit us during ASCO at booth 30149. #PrecisionOncology #ctDNA #ImmunoTherapy

Here are 3 things we can do to improve the physical and emotional recovery of Head and Neck Cancer patients. 1. Offer visual education about treatment and scanning technology, such as radiation therapy. 2. Establish Late Effects Clinics to treat side effects long term. 3. Use PROMS, Patient Reported Outcome Measures in routine clinical care to address individual issues of patient concern quickly and to collect clinical data on large groups of patients to inform improvements in care. In this video for World Head & Neck Cancer Day 2024 on 27 July, patients and clincians from the UK and Australia explain how we can achieve these goals. Mouth Cancer Foundation Geoff Delaney Puma Sundaresan Head and Neck Cancer Australia Trans Tasman Radiation Oncology Group (TROG Cancer Research) Radiation Oncology: Targeting Cancer #HNC #headandneckcancer #radonc #WHNCD #WHNCD24

#ASH23 | 🎥 The Multiple Myeloma Hub spoke to Danai Dima, Taussig Cancer Institute, Cleveland, US. We asked, What are the real-world outcomes following treatment with teclistamab in RRMM? Watch here: https://loom.ly/bAhi4Ao #mmsm #myeloma #MultipleMyeloma

Debbie’s Dream Foundation: Curing Stomach Cancer is proud to present an insightful interview with Dr. Samuel Klempner, GI Medical Oncologist of Massachusetts General Hospital Cancer Center and Harvard Medical School, titled "Ask the Expert: The Role of Biomarkers in Stomach Cancer." In the first snippet from this Q&A, Dr. Klempner discusses the importance of biomarker testing in the diagnosis and treatment of stomach cancer. Understanding the role of biomarkers can help guide personalized treatment plans and improve patient outcomes. To watch the full interview, visit https://lnkd.in/ewuZ8iZF. #KnowYourBiomarkers #stomachcancer #GastricCancer #DebbiesDreamFoundation #CancerResearch #genetictesting #Her2positive #Brcagene #MSIgene

The era of one-size-fits-all treatment in lung cancer is behind us. Today, precision medicine and biomarker-driven therapies are leading the charge in providing more personalized and effective treatment options for patients with non-small cell lung cancer (NSCLC). Biomarker testing provides crucial insights into the drivers of the disease, enabling doctors to chart the most effective treatment paths. Watch this video to explore our diverse range of products, designed to meet the unique needs of labs and patients alike, ensuring that every patient has access to the most advanced and effective care available: https://lnkd.in/ghnVexyC #LungCancer #BiomarkerTesting #PrecisionMedicine #NSCLC #AmoyDx #TargetedTherapy

🔴 DESTINY-Breast06: results support the use of trastuzumab deruxtecan in earlier lines of treatment for patients with metastatic #BreastCancer. 🗞️ Results from the phase 3, multicenter, open-label trial, recently published in The New England Journal of Medicine 👉 https://lnkd.in/dwDvKp_4 👩🔬 “These results are especially relevant since they suggest that treatment with this antibody drug conjugate, even at low HER2 expression levels, could be more effective in earlier lines of therapy compared with conventional chemotherapy, thus extending the potential benefits of HER2-directed therapy to an increasing number of patients,” concluded Cristina Saura Manich, Head of the Vall d'Hebron Barcelona Hospital Campus and the VHIO Breast Cancer Group. #BreastCancerAwareness #MamaVHIO #CancerResearch #Oncologia #BreastCancer | NEJM Group